Intended for healthcare professionals

Research

Antithrombin III in critically ill patients: systematic review with meta-analysis and trial sequential analysis

BMJ 2007; 335 doi: https://doi.org/10.1136/bmj.39398.682500.25 (Published 13 December 2007) Cite this as: BMJ 2007;335:1248
  1. Arash Afshari, senior resident 1,
  2. Jørn Wetterslev, staff specialist2,
  3. Jesper Brok, PhD student 2,
  4. Ann Møller, staff specialist 3
  1. 1Department of Anaesthesiology, Rigshospitalet, Juliane Marie Centre, University of Copenhagen, Copenhagen, Denmark
  2. 2Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen
  3. 3Cochrane Anaesthesia Group, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Ø, Copenhagen, Denmark
  1. Correspondence to: A Afshari arriba_a{at}yahoo.dk
  • Accepted 8 October 2007

Abstract

Objective To evaluate the benefits and harms of antithrombin III in critically ill patients.

Design Systematic review and meta-analysis of randomised trials.

Data sources CENTRAL, Medline, Embase, International Web of Science, LILACS, the Chinese Biomedical Literature Database, and CINHAL (to November 2006); hand search of reference lists, contact with authors and experts, and search of registers of ongoing trials.

Review methods Two reviewers independently selected parallel group randomised clinical trials comparing antithrombin with placebo or no intervention and extracted data related to study methods, interventions, outcomes, bias risk, and adverse events. Disagreements were resolved by discussion. Trials in any type of critically ill patients in intensive care were eligible. All trials, irrespective of blinding or language status, that compared any antithrombin III regimen with no intervention or placebo were included. Trials were considered to be at low risk of bias if they had adequate randomisation procedure, blinding, and used intention to treat analysis. Risk ratios with 95% confidence intervals were estimated with fixed and random effects models according to heterogeneity.

Main outcome measures Mortality, length of stay in intensive care or hospital, quality of life, severity of sepsis, respiratory failure, duration of mechanical ventilation, incidence of surgical intervention, intervention effect among various populations, and adverse events (such as bleeding).

Results 20 trials randomly assigning 3458 patients met inclusion criteria. Eight trials had low risk of bias. Compared with placebo or no intervention, antithrombin III did not reduce overall mortality (relative risk 0.96, 95% confidence interval 0.89 to 1.03). No subgroup analyses on risk of bias, populations of patients, or with and without adjuvant heparin yielded significant results. Antithrombin III increased the risk of bleeding events (1.52, 1.30 to 1.78). Heterogeneity was observed in only a few analyses.

Conclusion Antithrombin III cannot be recommended for critically ill patients based on the available evidence.

Footnotes

  • We thank J Albert, C Waydhas, S Opral, T Kobayashi, and F Fourrier for providing valuable additional data.

  • Contributors: AA and AM conceived and designed the study. AA and JW acquired analysed and interpreted data. All authors drafted and revised the review. AA and JW wrote to authors of papers for additional information. AA is guarantor.

  • Funding: None.

  • Competing interests: None declared.

  • Ethical approval: Not required.

  • Provenance and peer review: Not commissioned; externally peer reviewed.

  • Accepted 8 October 2007
View Full Text